Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Safex-500 is an oral antibiotic containing 500 mg of cefuroxime (likely as the prodrug cefuroxime axetil), a second-generation cephalosporin. Manufactured by Vintage Labs, it is indicated for the treatment of various bacterial infections, including respiratory tract infections (such as pneumonia and bronchitis), urinary tract infections, skin and soft tissue infections, and certain sexually transmitted diseases like gonorrhea. The drug's mechanism of action involves binding to penicillin-binding proteins (PBPs) located on the inner membrane of the bacterial cell wall. This binding inhibits the final transpeptidation step of peptidoglycan synthesis, which weakens the cell wall and leads to bacterial cell lysis and death.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Safex-500.